Bio-Bridge Announces Favorable Safety and Immunogenicity Results From Pre-clinical Study of Oral HIV Vaccine; Animal Studies Su
June 16 2006 - 7:49AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of vaccines
with broad preventative and therapeutic applications, today
announced that the Beijing Institute of Radiation Medicine has
notified the Company that it has completed the planned pre-clinical
safety and immunogenicity studies for Bio-Bridge's oral HIV
vaccine. In early February, Bio-Bridge Science received encouraging
initial results of the pre-clinical trials. Final results show no
toxicity was observed in the animals orally administered with the
HIV vaccine. There is no indication that vaccine DNA integrates
into host genome and passes through placenta barrier. The
immunogenicity study in monkeys shows that the vaccine induces
HIV-1 gp41-specific serum antibodies (IgG) and intestinal and
vaginal antibodies (sIgA). The sera, intestinal and vaginal
washings neutralize HIV-1 primary isolate in vitro. The vaccine
also induces HIV-1 Gag-specific T cells in the vaccinated monkeys.
"We are very pleased that the Beijing Institute of Radiation
Medicine has reported favorable safety and immunogenicity data on
our oral HIV vaccine," commented Liang Qiao, M.D., Chairman and CEO
of Bio-Bridge Science. "It is a major milestone in the development
of our HIV vaccine." Based on these favorable results, the company
is expected to file application for clinical trials with the
Chinese FDA in the near future. About Bio-Bridge Science:
Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine that is
expected to enter clinical trials this year in China. The vaccine,
based on exclusive technology co-developed by CEO Liang Qiao, an
associate professor at Loyola University Chicago's Strich School of
Medicine, targets infection in mucosal tissues, the first type of
tissue attacked by HIV. The Chinese government, mindful of the
rapid expansion of AIDS in China has, through the "Green Mile
Policy", acted to expedite the approval of domestically produced
HIV Vaccines. Bio-Bridge Science's GMP facility will also be used
to develop vaccines against cervical cancer and colon cancer under
the same technology platform as the HIV vaccine. Forward Looking
Statements This press release contains forward-looking statements
as defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are
expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to SEC filings
for additional information and accompanying notes to financial
statements.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024